Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP2215 (Gilteritinib) in Japanese Patients with R/R AML
NCT02181660Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Jun 2014
- Primary completion
- Jun 2016
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gilteritinib in acute myeloid leukemia (AML), sponsored by Astellas Pharma. Primary endpoint: Safety and Tolerability assessed through adverse events to determine maximum tolerated dose up to 17 months. Started Jun 2014; status: completed.
02
Drugs
gilteritinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02181660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02181660.